Charmingly eccentric, full of personality, and designed for maximum reader engagement
New Results for Dual Analysis of CTC-DNA and ctDNA using Illumina Assay
Findings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sample
ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, has announced successful results for their dual circulating tumour DNA (ctDNA) and CTC-DNA workflow using an end-to-end Illumina solution for analysis. By using Illumina assays and their NGS platform, ANGLE has overcome technical challenges to provide a complete solution for the dual analysis of CTCs and ctDNA in lung cancer research.
CTCs (circulating tumour cells) have been shown to contain additional biomarkers not found in ctDNA, making the dual analysis of both types of circulating tumour DNA crucial for a more comprehensive understanding of the disease. This breakthrough by ANGLE has the potential to revolutionize the way lung cancer is diagnosed and treated.
ANGLE has been invited to present their data at the EACR-Illumina webinar on 6 February 2025, showcasing the impact of their innovative approach to liquid biopsy technology in cancer research and clinical practice.
How This Will Affect Me
As a patient, this advancement in dual analysis of CTC-DNA and ctDNA could mean more accurate and personalized treatment options for lung cancer. By identifying additional biomarkers in CTCs, doctors may be able to tailor therapies to individual patients, leading to improved outcomes and quality of life.
How This Will Affect the World
The use of Illumina assays and NGS platforms for dual analysis of CTCs and ctDNA has the potential to revolutionize cancer research and precision medicine on a global scale. By providing a more comprehensive view of tumour biology, this technology could improve early detection, treatment selection, and overall survival rates for cancer patients worldwide.
Conclusion
ANGLE’s successful dual analysis of CTC-DNA and ctDNA using Illumina technology represents a significant step forward in liquid biopsy research. The potential impact on individual patients and the global cancer community is immense, paving the way for more personalized and effective treatments for lung cancer and beyond.
